MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Amgen Inc

Suletud

SektorTervishoid

279.7 0.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

273.64

Max

281.65

Põhinäitajad

By Trading Economics

Sissetulek

-2.2B

627M

Müük

586M

9.1B

P/E

Sektori keskmine

36.153

57.333

Aktsiakasum

5.31

Dividenditootlus

3.43

Kasumimarginaal

6.901

Töötajad

28,000

EBITDA

-517M

2.9B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+16.62% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.43%

2.63%

Järgmine tulemuste avaldamine

1. mai 2025

Järgmine dividendimakse kuupäev

6. juuni 2025

Järgmine aktsia dividendi kuupäev (ex-date)

16. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-6B

147B

Eelmine avamishind

279.11

Eelmine sulgemishind

279.7

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Amgen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. veebr 2025, 21:29 UTC

Tulu

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30. okt 2024, 20:18 UTC

Tulu

Amgen Posts Higher 3Q Sales on Strong Demand

10. apr 2025, 05:00 UTC

Tulu

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4. veebr 2025, 21:02 UTC

Tulu

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Adj EPS $5.31 >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Rev $9.1B >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q EPS $1.16 >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Net $627M >AMGN

28. jaan 2025, 10:30 UTC

Peamised uudised

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27. dets 2024, 07:00 UTC

Tulu

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23. dets 2024, 15:04 UTC

Peamised uudised

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13. dets 2024, 14:53 UTC

Peamised uudised

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30. nov 2024, 12:00 UTC

Peamised uudised

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26. nov 2024, 12:34 UTC

Peamised uudised

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4. nov 2024, 12:00 UTC

Peamised uudised

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30. okt 2024, 20:02 UTC

Tulu

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30. okt 2024, 20:02 UTC

Tulu

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30. okt 2024, 20:02 UTC

Tulu

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30. okt 2024, 20:02 UTC

Tulu

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30. okt 2024, 20:02 UTC

Tulu

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30. okt 2024, 20:01 UTC

Tulu

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30. okt 2024, 20:01 UTC

Tulu

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

Võrdlus sarnastega

Hinnamuutus

Amgen Inc Prognoos

Hinnasiht

By TipRanks

16.62% tõus

12 kuu keskmine prognoos

Keskmine 326.36 USD  16.62%

Kõrge 389 USD

Madal 280 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Amgen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

9

Osta

8

Hoia

1

Müü

Tehniline skoor

By Trading Central

278.68 / 295.18Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.